37 results on '"Lee, John Y. K."'
Search Results
2. Review of clinical trials in intraoperative molecular imaging during cancer surgery.
- Author
-
Lee, John Y. K., Cho, Steve S., Stummer, Walter, Tanyi, Janos L., Vahrmeijer, Alexander L., Rosenthal, Eben L., Smith, Barbara, Henderson, Eric R., Roberts, David W., Lee, Amy, Hadjipanayis, Constantinos G., Bruce, Jeffrey N., Newman, Jason G., and Singhal, Sunil
- Subjects
- *
ONCOLOGIC surgery , *IMAGING of cancer , *SURGICAL excision , *CLINICAL trials , *OPERATIVE surgery - Abstract
Most solid cancers are treated by surgical resections to reduce the burden of disease. Surgeons often face the challenge of detecting small areas of residual neoplasm after resection or finding small primary tumors for the initial resection. Intraoperative molecular imaging (IMI) is an emerging technology with the potential to dramatically improve cancer surgery operations by allowing surgeons to better visualize areas of neoplasm using fluorescence imaging. Over the last two years, two molecular optical contrast agents received U.S. Food and Drug Administration approval, and several more drugs are now on the horizon. Thus a conference was organized at the University of Pennsylvania to bring together oncologic surgeons from different specialties to discuss the current clinical status of IMI trials with a specific focus on phase 2 and phase 3 studies. In addition, phase 1 and experimental trials were also discussed briefly, to highlight other novel techniques. Our review summarizes the discussions from the conference and delves into the types of cancers discussed, different contrast agents in human trials, and the clinical value being studied. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Gamma Knife radiosurgery to four or more brain metastases in patients without prior intracranial radiation or surgery.
- Author
-
Ojerholm, Eric, Lee, John Y. K., Kolker, James, Lustig, Robert, Dorsey, Jay F., and Alonso‐Basanta, Michelle
- Subjects
- *
STEREOTACTIC radiosurgery , *RADIOTHERAPY , *METASTASIS , *BRAIN stimulation , *BRAIN diseases - Abstract
Data on stereotactic radiosurgery ( SRS) for four or more metastases are limited. Existing studies are confounded by significant proportions of patients receiving prior whole-brain radiation therapy ( WBRT) or concurrent WBRT with SRS. Furthermore, published results disagree about the impact of tumor volume on overall survival. A retrospective review identified 38 patients without prior intracranial radiation or surgery who received Gamma Knife ( GK) as sole treatment to ≥4 brain metastases in a single session. Twenty-eight cases with follow-up imaging were analyzed for intracranial progression. Prognostic factors were examined by univariate (log-rank test) and multivariate (Cox proportional hazards model) analyses. Common primary tumors were non-small cell lung (45%), melanoma (37%), and breast (8%). Cases were recursive partitioning analysis class II (94%) or III (6%). Patients harbored a median five tumors (range 4-12) with median total tumor volume of 1.2 cc. A median dose of 21 Gy was prescribed to the 50% isodose line. Patients survived a median 6.7 months from GK. Local treatment failure occurred in one case (4%) and distant failure in 22 (79%). On multivariate analysis, total tumor volume ≥3 cc was significantly associated with distant failure and worsened overall survival ( P = 0.042 and 0.040). Fourteen patients (37%) underwent salvage WBRT at a median 10.3 months from GK and seven patients received repeat GK. GK as sole initial treatment for four or more simultaneous metastases spares some patients WBRT and delays it for others. Increased total tumor volume (≥3 cc) is significantly associated with worsened overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Minimally Invasive, Robot-Assisted, Anterior Lumbar Interbody Fusion: A Technical Note.
- Author
-
Lee, John Y. K., Bhowmick, Deb A., Eun, Daniel D., and Welch, William C.
- Subjects
- *
LUMBAR vertebrae surgery , *SPINAL surgery , *DISSECTION , *POSTOPERATIVE pain , *EJACULATION , *SURGICAL robots - Abstract
Background Minimally invasive techniques in spine surgery have gained significant popularity due to decreased tissue dissection and destruction, postoperative pain, and hospital stay. The laparoscopic anterior lumbar interbody fusion (ALIF), an innovation in minimally invasive spine surgery, is rarely done because it has marginal benefit over the mini-open ALIF technique in rates of retrograde ejaculation and vascular complications. We propose these outcomes can be improved with enhanced robotic-assisted dissection and exposure for ALIF. Patients Two patients with single-level degenerative spine disease at L5-S1, associated with mechanical back pain, underwent anterior spinal exposure using the da Vinci S Surgical Robot during ALIF. Results In this report, we provide the first description of the use of a surgical robot in the dissection and exposure for ALIF in patients with degenerative spine disease. We demonstrate successful use of the da Vinci Surgical Robot in separating the presacral nervous plexus from retroperitoneal structures without postoperative vascular or urological complications over a 1-year follow-up period. Conclusion Use of the robotic assistance in the performance of ALIF is possible without significant operative complications. This technique may provide added benefit over conventional laparoscopic approaches to the spine. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
5. Endoscopic Endonasal Resection of Anterior Skull Base Meningiomas and Mucosa: Implications for Resection, Reconstruction, and Recurrence.
- Author
-
Lee, John Y. K., Barroeta, Julieta E., Newman, Jason G., Chiu, Alexander G., Venneti, Sriram, and Sean Grady, M.
- Subjects
- *
ENDOSCOPIC surgery , *SURGICAL excision , *SKULL surgery , *MENINGIOMA , *MUCOUS membranes , *CEREBROSPINAL fluid , *POSTERIOR cranial fossa , *SURGERY - Abstract
Background Meningiomas of the anterior skull base are attractive tumors for resection via an endoscopic endonasal route. The use of the vascularized Hadad-Bassagasteguy nasoseptal flap has dramatically reduced the cerebrospinal fluid (CSF) leak rate—the veritable Achilles heel of this surgical approach. Benign meningiomas, however, can erode through the nasal mucosa—the very same mucosa that is used to reconstruct the anterior cranial fossa floor. The goal of this study was to describe the presence of meningioma invasion into the mucosa in patients who underwent endoscopic endonasal resection of ventral skull base meningiomas. The implications of this finding are discussed with respect to resection, reconstruction, and recurrence. Patients, Materials, and Methods This is a retrospective review of three patients who underwent endoscopic endonasal complete resection of ventral skull base meningiomas. Surgically excised tissues were processed for routine histopathological analysis. Results A complete resection of the bone, dura, and tumor was performed in all three cases. Both patients with visual deficits improved. The first patient to undergo endoscopic surgical resection developed a CSF leak, but the later two patients with larger tumors did not. Histopathological analysis demonstrated mucosal invasion by World Health Organization (WHO) grade I meningioma in two of the three cases. Conclusion Ventral anterior skull base meningiomas can invade through bone into the mucosa. Because the endoscopic endonasal resection of these meningiomas often requires the use of a vascularized nasoseptal flap to minimize CSF leak complications, it is possible that the nasoseptal flap itself may be compromised by tumor tissue. The creation of the nasoseptal flap should take the findings of this study into consideration to minimize late recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
6. Intracranial extramedullary hematopoiesis associated with pilocytic astrocytoma: a case report.
- Author
-
Beckner, Marie E., Lee, John Y. K., Schochet, Sydney S., and Chu, Charleen T.
- Subjects
- *
HEMATOPOIESIS , *BONE marrow cells , *NERVOUS system , *CYTOKINES - Abstract
Intracranial EMH is only occasionally found in primary brain tumors (mostly hemangioblastomas) and, to our knowledge, this is the first case of EMH associated with an astrocytoma. Intracranial extramedullary hematopoiesis (EMH) is described in a 29-year-old man with a recurrent pilocytic astrocytoma in the tectal region. Special stains confirmed the identities of erythroid, myeloid and megakaryocytic cells. The patient had no evidence of a predisposing bone marrow disorder or systemic EMH. Although the presence of multinucleated and blastic cells associated with a low-grade brain neoplasm is unusual, recognition of hematopoietic lineages allows EMH to be readily identified. Another tumor resection after a year of follow-up confirmed the absence of malignant progression in this recurrent astrocytoma. The small number of cases describing intracranial EMH in the absence of systemic hematologic abnormalities are correlated with the findings in this case. The low incidence of intracranial EMH indicates that cells with hematopoietic potential are seldom exposed to a supportive microenvironment within the central nervous system. However, intracranial EMH should be included as a potential, ancillary diagnosis when considering brain lesions. This may be particularly true if medical therapies involving growth factors or stem cells are found to promote hematopoiesis. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
7. The use of aprepitant for the prevention of postoperative nausea and vomiting in endoscopic transsphenoidal pituitary surgery.
- Author
-
Lee, Daniel J., Douglas, Jennifer E., Chang, Jeremy, Wilensky, Jadyn, Jackson, Christina, Lee, John Y. K., Grady, Michael Sean, Yoshor, Daniel, Kohanski, Michael A., Palmer, James N., Atkins, Joshua H., and Adappa, Nithin D.
- Subjects
- *
POSTOPERATIVE nausea & vomiting , *ENDOSCOPIC surgery , *SKULL surgery , *SKULL base , *CEREBROSPINAL fluid leak , *SURGERY - Abstract
Background: Postoperative nausea and vomiting (PONV) are adverse effects after surgery, which may increase the risk of complications. Aprepitant is a neurokinin‐1 receptor blocker and has been shown to reduce chemotherapy‐related nausea and vomiting and PONV. However, its role in endoscopic skull base surgery remains unclear. The purpose of this study was to evaluate the effect of aprepitant in reducing PONV in endoscopic transsphenoidal (TSA) pituitary surgery. Methods: A retrospective chart review between July 2021 and January 2023 of 127 consecutive patients who underwent TSA was performed at a tertiary academic institution. Patients were divided into 2 groups based on preoperative aprepitant use. Two groups were matched based on known risk factors of PONV (age, sex, nonsmoking, and history of PONV). The primary outcome was the incidence of PONV. Secondary outcome measures included the number of anti‐emetic use, length of stay, and postoperative cererebrospinal fluid (CSF) leak. Results: After matching, 48 patients were included in each group. The aprepitant group demonstrated a significantly lower incidence of vomiting than the non‐aprepitant group (2.1% vs 22.9%, p = 0.002). The number of nausea episodes and anti‐emetic use decreased with aprepitant use (p < 0.05). There was no difference in the incidence of nausea, length of stay, or postoperative CSF leak. Multivariate analysis demonstrated that aprepitant decreased the incidence of postoperative vomiting with odds ratio of 0.107. Conclusion: Aprepitant may serve as a useful preoperative treatment to reduce PONV in patients undergoing TSA. Further studies are needed to evaluate its impact in other arenas of endoscopic skull base surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Factors Associated with and Temporal Trends in the Use of Radiation Therapy for the Treatment of Pituitary Adenoma in the National Cancer Database.
- Author
-
Fathy, Ramie, Kuan, Edward, Lee, John Y. K., Grady, M Sean, Alonso-Basanta, Michelle, Palmer, James N., Adappa, Nithin D., O'Malley, Bert W., and Brant, Jason
- Subjects
- *
ADENOMATOUS polyps , *PITUITARY tumors , *RADIOTHERAPY , *TEMPORAL databases , *ACADEMIC medical centers , *DIAGNOSIS , *BENIGN tumors - Abstract
Objective Radiation therapy represents an uncommon but important component of treatment plans for some pituitary adenomas (PAs). Although radiation therapy has been used to treat pituitary adenomas for over a century, general trends in the usage of radiation therapy for this purpose have not been reviewed. Additionally, there are few large studies evaluating how radiation therapy is used for the treatment of these benign tumors. Investigating these trends and identifying any variations in radiation therapy utilization would help to better inform treatment decisions and improve patient outcomes. Design Present study is a retrospective analysis of cases using the National Cancer Database. Setting The research was organized at a tertiary academic medical center. Participants Patients were diagnosed with pituitary adenoma between 2004 and 2014 within the National Cancer Database (NCDB). Methods Temporal trends in the usage of radiation therapy to treat pituitary adenoma were analyzed through a retrospective analysis of 77,142 pituitary adenoma cases from the NCDB between 2004 and 2014. Univariate and multivariate analyses were to examine the relationship between patient, tumor, and treatment factors, and the incorporation of radiation therapy into the treatment of pituitary adenomas. We adjusted for potential confounders such as age, sex, race, comorbidity score, facility type, and year of diagnosis. Results A total of 77,142 patients met inclusion criteria. Inclusion of radiation therapy in pituitary adenoma treatment was 8.0% in 2004 and steadily declined to a low of 3.1% in 2014. Overall, patients were less likely to receive radiation for their pituitary adenoma over time (p < 0.001). Similarly, patients were found to be less likely to receive any type of treatment for PA over time (p < 0.001). Multivariable evaluation found patients who were female, between 54 and 64 years of age, or treated at either a Comprehensive Community Cancer Program or an Integrated Network Cancer Program were more likely to receive radiation as part of their pituitary adenoma treatment (p < 0.001, odds ratio [OR] = 2.01, confidence interval [CI]: 1.54–2.63; p < 0.001, OR = 1.84, CI: 1.38–2.44, respectively). Patients were less likely to receive radiation for their PA if they were African American (p < 0.001, OR = 0.81, CI: 0.72–0.91). Logistic regression also identified a progressive increase in the likelihood of receiving radiation after a PA diagnosis with increasing tumor size starting with microscopic tumors, peaking at 4 to 5 cm (p < 0.001; OR = 15.57; CI: 12.20–19.87). Conclusion In this sample of pituitary adenoma patients treated at NCDB institutions between 2004 and 2014, we found a steady decline in the incorporation of radiation therapy in treatment, as well as in the use of any type of intervention for PA treatment, suggesting a rise in noninterventional observation of PA. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Orbital resection by intranasal technique (ORBIT): A new classification system for reporting endoscopically resectable primary benign orbital tumors.
- Author
-
Jafari, Aria, Adappa, Nithin D., Anagnos, Vincent J., Campbell, Raewyn G., Castelnuovo, Paolo, Chalian, Ara, Chambers, Christopher B., Chitguppi, Chandala, Dallan, Iacopo, El Rassi, Edward, Freitag, Suzanne K., Fernandez Miranda, Juan C., Ferreira, Manuel, Gardner, Paul A., Gudis, David A., Harvey, Richard J., Huang, Qian, Humphreys, Ian M., Kennedy, David W., and Lee, John Y. K.
- Subjects
- *
BENIGN tumors , *ORBITS (Astronomy) , *CAVERNOUS hemangioma , *FISHER exact test ,EYE-socket tumors - Abstract
Background: The Cavernous Hemangioma Exclusively Endonasal Resection (CHEER) staging system has become the gold standard for outcomes reporting in endoscopic orbital surgery for orbital cavernous hemangiomas (OCHs). A recent systematic review demonstrated similar outcomes between OCHs and other primary benign orbital tumors (PBOTs). Therefore, we hypothesized that a simplified and more comprehensive classification system could be developed to predict surgical outcomes of other PBOTs. Methods: Patient and tumor characteristics as well as surgical outcomes from 11 international centers were recorded. All tumors were retrospectively assigned an Orbital Resection by Intranasal Technique (ORBIT) class and stratified based on surgical approach as either exclusively endoscopic or combined (endoscopic and open). Outcomes based on approach were compared using chi‐squared or Fisher's exact tests. The Cochrane‐Armitage test for trend was used to analyze outcomes by class. Results: Findings from 110 PBOTs from 110 patients (age 49.0 ± 15.0 years, 51.9% female) were included in the analysis. Higher ORBIT class was associated with a lower likelihood of gross total resection (GTR). GTR was more likely to be achieved when an exclusively endoscopic approach was utilized (p < 0.05). Tumors resected using a combined approach tended to be larger, to present with diplopia, and to have an immediate postoperative cranial nerve palsy (p < 0.05). Conclusion: Endoscopic treatment of PBOTs is an effective approach, with favorable short‐term and long‐term postoperative outcomes as well as low rate of adverse events. The ORBIT classification system is an anatomic‐based framework that effectively facilitates high‐quality outcomes reporting for all PBOTs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI.
- Author
-
de Godoy, Laiz Laura, Lim, Kheng Choon, Rajan, Archith, Verma, Gaurav, Hanaoka, Mauro, O'Rourke, Donald M., Lee, John Y. K., Desai, Arati, Chawla, Sanjeev, and Mohan, Suyash
- Subjects
- *
GENETIC mutation , *PREDICTIVE tests , *PROTON magnetic resonance spectroscopy , *IMMUNOHISTOCHEMISTRY , *GLIOMAS , *MANN Whitney U Test , *DESCRIPTIVE statistics , *CHI-squared test , *OXIDOREDUCTASES , *TUMOR markers , *RECEIVER operating characteristic curves , *DATA analysis software , *SENSITIVITY & specificity (Statistics) , *METABOLITES - Abstract
Simple Summary: IDH mutation is one of the most important prognostic biomarkers in glioma management. Noninvasive neuroimaging techniques to predict IDH mutant glioma may be valuable for guiding clinical decision-making and monitoring response to targeted therapies. The aim of our prospective study was to investigate the clinical potential of proton MR spectroscopy (1H-MRS) with an optimized TE (97 ms) in identifying IDH-mutant gliomas by detecting characteristic resonances of 2HG and its complex interplay with other clinically relevant metabolites. We confirmed that the oncometabolite 2HG was found to be significant in predicting IDH-mutant gliomas, and both single-voxel and multi-voxel 1H-MRS methods are equally efficient in detecting complex resonances of 2HG. Additionally, Glx (glutamate + glutamine) and NAA (N-acetylaspartate) were also found to be important in distinguishing IDH-mutant from wild-type gliomas. In short, 1H-MRS with an optimized TE may be helpful for noninvasively detecting the abnormally high levels of 2HG with high accuracy and comprehending its interaction with other relevant metabolites in infiltrative gliomas. Purpose: The isocitrate dehydrogenase (IDH) mutation has become one of the most important prognostic biomarkers in glioma management, indicating better treatment response and prognosis. IDH mutations confer neomorphic activity leading to the conversion of alpha-ketoglutarate (α-KG) to 2-hydroxyglutarate (2HG). The purpose of this study was to investigate the clinical potential of proton MR spectroscopy (1H-MRS) in identifying IDH-mutant gliomas by detecting characteristic resonances of 2HG and its complex interplay with other clinically relevant metabolites. Materials and Methods: Thirty-two patients with suspected infiltrative glioma underwent a single-voxel (SVS, n = 17) and/or single-slice-multivoxel (1H-MRSI, n = 15) proton MR spectroscopy (1H-MRS) sequence with an optimized echo-time (97 ms) on 3T-MRI. Spectroscopy data were analyzed using the linear combination (LC) model. Cramér–Rao lower bound (CRLB) values of <40% were considered acceptable for detecting 2HG and <20% for other metabolites. Immunohistochemical analyses for determining IDH mutational status were subsequently performed from resected tumor specimens and findings were compared with the results from spectral data. Mann–Whitney and chi-squared tests were performed to ascertain differences in metabolite levels between IDH-mutant and IDH-wild-type gliomas. Receiver operating characteristic (ROC) curve analyses were also performed. Results: Data from eight cases were excluded due to poor spectral quality or non-tumor-related etiology, and final data analyses were performed from 24 cases. Of these cases, 9/12 (75%) were correctly identified as IDH-mutant or IDH-wildtype gliomas through SVS and 10/12 (83%) through 1H-MRSI with an overall concordance rate of 79% (19/24). The sensitivity, specificity, positive predictive value, and negative predictive value were 80%, 77%, 86%, and 70%, respectively. The metabolite 2HG was found to be significant in predicting IDH-mutant gliomas through the chi-squared test (p < 0.01). The IDH-mutant gliomas also had a significantly higher NAA/Cr ratio (1.20 ± 0.09 vs. 0.75 ± 0.12 p = 0.016) and lower Glx/Cr ratio (0.86 ± 0.078 vs. 1.88 ± 0.66; p = 0.029) than those with IDH wild-type gliomas. The areas under the ROC curves for NAA/Cr and Glx/Cr were 0.808 and 0.786, respectively. Conclusions: Noninvasive optimized 1H-MRS may be useful in predicting IDH mutational status and 2HG may serve as a valuable diagnostic and prognostic biomarker in patients with gliomas [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Second window indocyanine green localizes CNS lymphoma in real time in the operating room: report of two cases.
- Author
-
Henderson Jr., Fraser, Brem, Steven, Hussain, Jasmin, Buch, Love, Maloney, Eileen, Singhal, Sunil, and Lee, John Y. K.
- Subjects
- *
INDOCYANINE green , *OPERATING rooms , *B cell lymphoma , *LYMPHOMAS , *POLYPOIDAL choroidal vasculopathy , *CENTRAL nervous system - Abstract
Intraoperative distinction of lesional tissue versus normal brain parenchyma can be difficult in neurosurgical oncology procedures. We report the successful, real-time visualization of central nervous system (CNS) lymphoma using the 'Second Window Indocyanine Green' (SWIG) method for two patients who underwent craniotomy for pathology that was determined to be large B cell lymphoma. Indocyanine green (ICG), when administered intravenously the day prior to cranial surgery, is a re-purposed fluorophore that may afford safe, immediate visual confirmation of on-target tissue resection, thereby providing a valuable adjunct to intraoperative navigation and decreasing reliance on frozen pathology analysis. These first reported cases of SWIG for lymphoma in the CNS indicate that further study of fluorophores to improve biopsy targeting and yield is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. A Cost-Effectiveness Review of Genetic Testing of Paragangliomas.
- Author
-
Abbasi, Aleena A., Lustig, Robert A., Dorsey, Jay F., Grady, Sean M., Lee, John Y. K., Kurtz, Goldie A., Shabason, Jacob E., Bigelow, Douglas C., Brant, Jason A., Ruckenstein, Michael J., Nathanson, Katherine L., Raper, Anna, and Alonso-Basanta, Michelle
- Subjects
- *
GENETIC testing , *COST effectiveness - Published
- 2023
- Full Text
- View/download PDF
13. Short- and Long-Term Pain Outcomes Following Endoscopic Microvascular Decompression for Trigeminal Neuralgia Based on Vascular Compression Type.
- Author
-
Blue, Rachel, Yang, Andrew I., Ajmera, Sonia, Spadola, Michael, and Lee, John Y. K.
- Subjects
- *
TRIGEMINAL neuralgia , *DECOMPRESSION (Physiology) - Published
- 2023
- Full Text
- View/download PDF
14. Refractory glossopharyngeal neuralgia successfully treated with onabotulinumtoxinA: A case report.
- Author
-
Hamilton, Katherine T., Seligman, Rachel, Blue, Rachel, and Lee, John Y. K.
- Subjects
- *
BOTULINUM toxin , *HIV-positive persons , *CRANIAL nerve diseases , *CHRONIC diseases , *MIGRAINE , *SURGICAL decompression , *GLOSSOPHARYNGEAL nerve , *TREATMENT effectiveness , *DISEASE relapse , *DISEASE remission , *SYMPTOMS - Abstract
Background: Glossopharyngeal neuralgia is a rare but severe and disabling pain condition often caused by vascular compression of the glossopharyngeal nerve. Treatment is similar to that of trigeminal neuralgia, but some patients may be refractory to both medical and surgical approaches. Here we present a case of refractory glossopharyngeal neuralgia that responded well to onabotulinumtoxinA (BTX‐A). Case: We report a case of a 65‐year‐old man with well‐controlled human immunodeficiency virus disease with glossopharyngeal neuralgia symptoms since 2015. He had partial response to medications but was limited by side‐effects. He underwent microvascular decompression twice with initial relief both times, but experienced recurrence of attacks 1–3 years after each surgery. He was treated with BTX‐A using the chronic migraine PREEMPT protocol (i.e., 31–39 injection sites in head and neck muscles), which led to significant relief of his glossopharyngeal neuralgia pain. Conclusions: This is the first case to our knowledge of glossopharyngeal neuralgia treated with BTX‐A. BTX‐A can be an effective treatment for glossopharyngeal neuralgia, even when injections are not administered directly over the sensory distribution of the glossopharyngeal nerve. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. In-Hospital Costs Associated With an Expanded Endonasal Approach to Anterior Skull Base Tumors.
- Author
-
Parasher, Arjun K., Lerner, David K., Glicksman, Jordan T., Lin, Theodore, Miranda, Stephen P., Ebesutani, Darren, Kohanski, Michael, Lee, John Y. K., Storm, Phillip B., O'Malley Jr., Bert W., Yosher, Daniel, Palmer, James N., Grady, Sean, and Adappa, Nithin D.
- Subjects
- *
STATISTICS , *CEREBROSPINAL fluid leak , *CONFIDENCE intervals , *NEUROSURGERY , *ENDOSCOPIC surgery , *DIABETES insipidus , *HOSPITAL costs , *MEDICAL care costs , *ACQUISITION of data , *SURGICAL complications , *COST control , *NASAL septum , *MENINGIOMA , *MEDICAL records , *PITUITARY tumors , *DESCRIPTIVE statistics , *SKULL base , *DATA analysis software , *WHITE people , *SKULL tumors , *ENDOSCOPY , *MEDICAL specialties & specialists , *AFRICAN Americans ,SURGERY practice - Abstract
Objective: To determine in-hospital costs associated with performing an EEA to anterior skull base pathology and to identify drivers of cost variability for patients undergoing endoscopic anterior skull base surgery. Methods: All endoscopic anterior skull base surgeries performed over a period from January 1st, 2015 to October 24th, 2017 were evaluated. The electronic medical record was reviewed for patient factors, tumor characteristics, and cost variables associated with each hospital stay and univariate analysis was performed using Stata software. Results: An EEA was associated with an average total in-hospital cost of $44 545. Compared to patients undergoing a transsphenoidal approach to pituitary tumor resection, EEA patients incurred higher in-hospital costs across all variables including a total cost increase of $15 921 (95% confidence interval $5720-26 122, P =.002). Univariate analysis of all endoscopic anterior skull base surgery patients showed a cost increase of $30 616 associated with post-operative cerebrospinal fluid (CSF) leak ($10 420-50 811, P =.004), $14 610 with post-operative diabetes insipidus (DI) ($4610-24 609, P =.004), and $11 522 with African-American patients relative to Caucasian patients ($3049-19 995, P =.008). Conclusions: Patients who undergo endoscopic EEA for resection of anterior skull base tumors typically incur greater in-hospital costs than patients undergoing a standard TSA. Post-operative complications such as CSF leak and DI, as well as ethnicity, are significant drivers of cost-variability. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Second window indocyanine green for oropharyngeal tumours: A case series and comparison of near‐infrared camera systems.
- Author
-
De Ravin, Emma, Carey, Ryan M., Stubbs, Vanessa C., Jaffe, Samantha, Lee, John Y. K., Rajasekaran, Karthik, and Newman, Jason G.
- Subjects
- *
HEAD & neck cancer , *INDOCYANINE green , *TUMORS , *SURGICAL margin , *CAMERAS , *RECTAL surgery - Abstract
We also did not conduct performance characterisation studies and relied upon imaging and infusion protocols from a prior proof of concept study.12 The fluorophore dose and imaging time points were not individually optimised for each of the imaging platforms, but these techniques have demonstrated efficacy in NIR imaging of multiple malignancies.14-16 Finally, our study relies upon the primary surgeon's subjective impression of tumour NIR fluorescence and adequate tumour-margin delineation, rather than a standardised, quantifiable measure of fluorescence. Head and neck cancer, indocyanine green dye, intraoperative imaging, optical imaging, near-infrared imaging, precision surgery In this study, we compared the performance of a surgical robot-integrated NIR camera system to a dedicated NIR imaging platform for SWIG imaging during TORS for OPSCC. Keywords: head and neck cancer; indocyanine green dye; intraoperative imaging; near-infrared imaging; optical imaging; precision surgery EN head and neck cancer indocyanine green dye intraoperative imaging near-infrared imaging optical imaging precision surgery 589 593 5 08/05/22 20220901 NES 220901 Key Points Prior studies demonstrated a failure to identify and localise head and neck cancers via near-infrared (NIR) imaging of indocyanine green (ICG) with a robot-integrated platform. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
17. Assessment and Comparison of Three Dimensional Exoscopes for Near-Infrared Fluorescence-Guided Surgery Using Second-Window Indocyanine-Green.
- Author
-
Cho, Steve S., Teng, Clare W., De Ravin, Emma, Singh, Yash B., and Lee, John Y. K.
- Subjects
- *
MICROSURGERY , *IMAGING systems ,CENTRAL nervous system tumors - Abstract
Objective: Compared to microscopes, exoscopes have advantages in field-depth, ergonomics, and educational value. Exoscopes are especially well-poised for adaptation into fluorescence-guided surgery (FGS) due to their excitation source, light path, and image processing capabilities. We evaluated the feasibility of near-infrared FGS using a 3-dimensional (3D), 4 K exoscope with nearinfrared fluorescence imaging capability. We then compared it to the most sensitive, commercially-available near-infrared exoscope system (3D and 960 p). In-vitro and intraoperative comparisons were performed. Methods: Serial dilutions of indocyanine-green (1-2000 µg/mL) were imaged with the 3D, 4 K Olympus Orbeye (system 1) and the 3D, 960 p VisionSense Iridium (system 2). Near-infrared sensitivity was calculated using signal-to-background ratios (SBRs). In addition, three patients with brain tumors were administered indocyanine-green and imaged with system 1, with two also imaged with system 2 for comparison. Results: Systems 1 and 2 detected near-infrared fluorescence from indocyanine green concentrations of >250 µg/L and >31.3 µg/L, respectively. Intraoperatively, system 1 visualized strong near-infrared fluorescence from two, strongly gadoliniumenhancing meningiomas (SBR=2.4, 1.7). The high-resolution, bright images were sufficient for the surgeon to appreciate the underlying anatomy in the near-infrared mode. However, system 1 was not able to visualize fluorescence from a weakly-enhancing intraparenchymal metastasis. In contrast, system 2 successfully visualized both the meningioma and the metastasis but lacked high resolution stereopsis. Conclusion: Three-dimensional exoscope systems provide an alternative visualization platform for both standard microsurgery and near-infrared fluorescent guided surgery. However, when tumor fluorescence is weak (i.e., low fluorophore uptake, deep tumors), highly sensitive near-infrared visualization systems may be required. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Gamma Knife radiosurgery for trigeminal neuralgia provides greater pain relief at higher dose rates.
- Author
-
Yang, Andrew I., Mensah-Brown, Kobina G., Shekhtman, Emily F., Kvint, Svetlana, Wathen, Connor A., Hitti, Frederick L., Alonso-Basanta, Michelle, Avery, Stephen M., Dorsey, Jay F., and Lee, John Y. K.
- Subjects
- *
RADIOSURGERY , *TRIGEMINAL neuralgia , *ANALGESIA , *FACIAL pain , *LIFE cycles (Biology) , *RADIATION injuries , *NEURALGIA - Abstract
In Gamma Knife (GK) radiosurgery, dose rate decreases during the life cycle of its radiation source, extending treatment times. Prolonged treatments influence the amount of sublethal radiation injury that is repaired during exposure, and is associated with decreased biologically-equivalent dose (BED). We assessed the impact of treatment times on clinical outcomes following GK of the trigeminal nerve - a rare clinical model to isolate the effects of treatment times. This is a retrospective analysis of 192 patients with facial pain treated across three source exchanges. All patients were treated to 80 Gy with a single isocenter. Treatment time was analyzed in terms of patient anatomy-specific dose rate, as well as BED calculated from individual patient beam-on times. An outcome tool measuring pain in three distinct domains (pain intensity, interference with general and oro-facial activities of daily living), was administered before and after intervention. Multivariate linear regression was performed with dose rate/BED, brainstem dose, sex, age, diagnosis, and prior intervention as predictors. BED was an independent predictor of the degree of improvement in all three dimensions of pain severity. A decrease in dose rate by 1.5 Gy/min corresponded to 31.8% less improvement in the overall severity of pain. Post-radiosurgery incidence of facial numbness was increased for BEDs in the highest quartile. Treatment time is an independent predictor of pain outcomes, suggesting that prescription dose should be customized to ensure iso-effective treatments, while accounting for the possible increase in adverse effects at the highest BEDs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
19. Fully Endoscopic Microvascular Decompression: Our Early Experience.
- Author
-
Halpern, Casey H., Shih-Shan Lang, and Lee, John Y. K.
- Subjects
- *
SURGICAL decompression , *ENDOSCOPIC surgery , *NEUROVASCULAR surgery , *NEUROVASCULAR diseases , *ENDOSCOPES , *THERAPEUTICS - Abstract
Background. Microvascular decompression (MVD) is a widely accepted treatment for neurovascular disorders associated with facial pain and spasm. The endoscope has rapidly become a standard tool in neurosurgical procedures; however, its adoption in lateral approaches to the posterior fossa has been slower. The endoscope is used primarily to assist conventional microscopic techniques. We are interested in developing fully endoscopic approaches to the cerebellopontine angle, and here, we describe our preliminary experience with this procedure for MVD. Methods. A retrospective review of our two-year experience from 2011 to 2012, transitioning fromusing conventional microscopic techniques to endoscope-assisted microsurgery to fully endoscopicMVD, is provided. We also reviewed our preliminary outcomes during this transition. Results. There was no difference in the surgical duration of these three procedures. In addition, the majority of procedures performed in 2012 were fully endoscopic, suggesting the ease of incorporating this solo tool into practice. Pain outcomes of fully endoscopic MVD appear to be very similar to those of both conventional and endoscope-assisted MVDs. Complications occurred in all groups at equally low rates. Conclusion. Fully endoscopic MVD is both safe and effective. By enhancing visualization of structures within the cerebellopontine angle, endoscopy may prove to be a valuable adjunct or alternative to conventional microscopic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
20. Evaluation of Diagnostic Accuracy Following the Coadministration of Delta-Aminolevulinic Acid and Second Window Indocyanine Green in Rodent and Human Glioblastomas.
- Author
-
Cho, Steve S., Sheikh, Saad, Teng, Clare W., Georges, Joseph, Yang, Andrew I., De Ravin, Emma, Buch, Love, Li, Carrie, Singh, Yash, Appelt, Denah, Delikatny, Edward J., Petersson, E. James, Tsourkas, Andrew, Dorsey, Jay, Singhal, Sunil, and Lee, John Y. K.
- Subjects
- *
INDOCYANINE green , *RODENTS , *FLUORESCENCE ,TUMOR surgery - Abstract
Purpose: Fluorescence-guided-surgery offers intraoperative visualization of neoplastic tissue. Delta-aminolevulinic acid (5-ALA), which targets enzymatic abnormality in neoplastic cells, is the only approved agent for fluorescence-guided neurosurgery. More recently, we described Second Window Indocyanine Green (SWIG) which targets neoplastic tissue through enhanced vascular permeability. We hypothesized that SWIG would demonstrate similar clinical utility in identification of high-grade gliomas compared with 5-ALA. Procedures: Female C57/BL6 and nude/athymic mice underwent intracranial implantation of 300,000 GL261 and U87 cells, respectively. Tumor-bearing mice were euthanized after administration of 5-ALA (200 mg/kg intraperitoneal) and SWIG (5 mg/kg intravenous). Brain sections were imaged for protoporphyrin-IX and ICG fluorescence. Fluorescence and H&E images were registered using semi-automatic scripts for analysis. Human subjects with HGG were administered SWIG (2.5 mg/kg intravenous) and 5-ALA (20 mg/kg oral). Intraoperatively, tumors were imaged for ICG and protoporphyrin-IX fluorescence. Results: In non-necrotic tumors, 5-ALA and SWIG demonstrated 90.2 % and 89.2 % tumor accuracy (p value = 0.52) in U87 tumors and 88.1 % and 87.7 % accuracy (p value = 0.83) in GL261 tumors. The most distinct difference between 5-ALA and SWIG distribution was seen in areas of tumor-associated necrosis, which often showed weak/no protoporphyrin-IX fluorescence, but strong SWIG fluorescence. In twenty biopsy specimens from four subjects with HGG, SWIG demonstrated 100 % accuracy, while 5-ALA demonstrated 75–85 % accuracy; there was 90 % concordance between SWIG and 5-ALA fluorescence. Conclusion: Our results provide the first direct comparison of the diagnostic utility of SWIG vs 5-ALA in both rodent and human HGG. Given the broader clinical utility of SWIG compared with 5-ALA, our data supports the use of SWIG in tumor surgery to improve the extent of safe resections. Clinical Trial: NCT02710240 (US National Library of Medicine Registry; https://www.clinicaltrials.gov/ct2/show/NCT02710240?id=NCT02710240&draw=2&rank=1). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Near-Infrared Imaging with Second-Window Indocyanine Green in Newly Diagnosed High-Grade Gliomas Predicts Gadolinium Enhancement on Postoperative Magnetic Resonance Imaging.
- Author
-
Cho, Steve S., Salinas, Ryan, De Ravin, Emma, Teng, Clare W., Li, Carrie, Abdullah, Kalil G., Buch, Love, Hussain, Jasmin, Ahmed, Fahad, Dorsey, Jay, Mohan, Suyash, Brem, Steven, Singhal, Sunil, and Lee, John Y. K.
- Subjects
- *
INDOCYANINE green , *MAGNETIC resonance imaging , *GLIOMAS , *GADOLINIUM - Abstract
Purpose: Intraoperative molecular imaging with tumor-targeting fluorophores offers real-time detection of neoplastic tissue. The second window indocyanine green (SWIG) technique relies on passive accumulation of indocyanine green (ICG), a near-infrared fluorophore, in neoplastic tissues. In this study, we explore the ability of SWIG to detect neoplastic tissue and to predict postoperative magnetic resonance imaging (MRI) findings intraoperatively.Procedures: Retrospective data were collected from 36 patients with primary high-grade gliomas (HGG) enrolled as part of a larger trial between October 2014 and October 2018. Patients received systemic ICG infusions at 2.5-5 mg/kg 24 h preoperatively. Near-infrared fluorescence was recorded throughout the case and from biopsy specimens. The presence/location of residual SWIG signal after resection was compared to the presence/location of residual gadolinium enhancement on postoperative MRI. The extent of resection was not changed based on near-infrared imaging.Results: All 36 lesions demonstrated strong near-infrared fluorescence (signal-to-background = 6.8 ± 2.2) and 100 % of tumors reaching the cortex were visualized before durotomy. In 78 biopsy specimens, near-infrared imaging demonstrated higher sensitivity and accuracy than white light for diagnosing neoplastic tissue intraoperatively. Furthermore, near-infrared imaging predicted gadolinium enhancement on postoperative MRI with 91 % accuracy, with visualization of residual enhancement as small as 0.3 cm3. Patients with no residual near-infrared signal after resection were significantly more likely to have complete resection on postoperative MRI (p value < 0.0001).Conclusions: Intraoperative imaging with SWIG demonstrates highly sensitive detection of HGG tissue in real time. Furthermore, post-resection near-infrared imaging correlates with postoperative MRI. Overall, our findings suggest that SWIG can provide surgeons with MRI-like results in real time, potentially increasing resection rates. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
22. Smell Preservation following Unilateral Endoscopic Transnasal Approach to Resection of Olfactory Groove Meningioma: A Multi-institutional Experience.
- Author
-
Orgain, Carolyn A., Kuan, Edward C., Alvarado, Raquel, Adappa, Nithin D., Jonker, Benjamin P., Lee, John Y. K., Palmer, James N., Winder, Mark, and Harvey, Richard J.
- Subjects
- *
SMELL , *OLFACTORY bulb , *RHINORRHEA , *OLFACTOMETRY , *ENDOSCOPIC surgery , *MENINGIOMA , *MAGNETIC resonance imaging - Abstract
Introduction Olfactory groove meningiomas (OGMs) are often associated with loss of smell following resection. Loss of smell has a measurable impact on quality of life. Smell preservation has been previously described in open approaches for early stage or unilateral OGMs. Evidence of smell preservation in endoscopic approaches is lacking. Design A multi-institutional retrospective review was performed on consecutive patients who underwent unilateral endoscopic endonasal resection of OGM. A gross total resection was achieved with preservation of the contralateral olfactory cleft and bulb. Olfactory function was assessed with a six-point olfactory symptom score and the Sniffin' Sticks 12-item smell identification test (SS-12). Contralateral olfactory bulb volume was measured on postoperative magnetic resonance imaging. Results Four patients (age 42.0 ± 7.5, 75% female) were assessed. Olfactory function was assessed at 21.8 ± 5.6 months following surgery. All patients reported some degree of smell preservation (75% described a slight/mild impairment in smell or better). Olfactory identification was preserved with an SS-12 score of 9 ± 1.4 (anosmia defined as ≤6). The olfactory bulb volume was calculated to be 47.4 ± 15.9 mm 3 (normal >40 mm 3). Conclusion Smell preservation is possible following unilateral endoscopic endonasal resection of carefully selected OGM. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy.
- Author
-
Miccio, Joseph A., Barsky, Andrew, Gao, Sarah, Verma, Vivek, Noticewala, Sonal S., Jairam, Vikram, Johnson, Skyler B., Yu, James B., Hansen, James E., Aneja, Sanjay, Yi An, Decker, Roy H., Omay, S. Bulent, Li, Jing, Kurtz, Goldie A., Alonso-Basanta, Michelle, Lee, John Y. K., Chiang, Veronica L., and Park, Henry S.
- Subjects
- *
SMALL cell lung cancer , *STEREOTACTIC radiosurgery , *BRAIN metastasis - Abstract
Introduction: Patients with small cell lung cancer (SCLC) brain metastasis (BM) typically receive whole brain radiotherapy (WBRT) as data regarding upfront radiosurgery (SRS) in this setting are sparse. Methods: Patients receiving SRS for SCLC BM without prior brain radiation were identified at three U.S. institutions. Overall survival (OS), freedom from intracranial progression (FFIP), freedom from WBRT (FFWBRT), and freedom from neurologic death (FFND) were determined from time of SRS. Results: Thirty-three patients were included with a median of 2 BM (IQR 1-6). Median OS and FFIP were 6.7 and 5.8 months, respectively. Median FFIP for patients with =2 versus >2 BM was 7.1 versus 3.6 months, p=0.0303. Eight patients received salvage WBRT and the 6-month FFWBRT and FFND were 87.8%. and 90.1%, respectively. Conclusions: Most SCLC patients with BM who received upfront SRS avoided WBRT and neurologic death, suggesting that SRS may be an option in select patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
24. Near-infrared intraoperative molecular imaging with conventional neurosurgical microscope can be improved with narrow band "boost" excitation.
- Author
-
Li, Carrie, Buch, Love, Cho, Steve, and Lee, John Y. K.
- Subjects
- *
CLINICAL trial registries , *MICROSCOPES , *INTRAOPERATIVE radiotherapy , *GLIOBLASTOMA multiforme , *INDOCYANINE green , *BRAIN tumors - Abstract
Background: Intraoperative visualization of brain tumors with near-infrared (NIR)-fluorescent dyes is an emerging method for tumor margin approximation but are limited by existing fluorescence detection platforms. We previously showed that a dedicated NIR imaging platform outperformed a state-of-the-art neurosurgical microscope in fluorescence signal characteristics. This study examined whether conventional neurosurgical microscope NIR signal could be improved with the addition of a narrow wavelength excitation source. Methods: Imaging was conducted with a broad-spectrum neurosurgical microscope and commercial near-infrared module. Addition of an 805-nm laser was used to "boost" NIR excitation of indocyanine green (ICG). In vitro quantification was performed on serial dilutions of ICG. Patients underwent tumor resection with delayed 24-h imaging of ICG infusion. NIR fluorescence of dura, cortex, or tumor was quantified from images prior to (pre-boost) and following added excitation with the laser (post-boost). Signal to background ratio (SBR) of pre- and post-boost was calculated as a readout of image enhancement. Results: In vitro, excitation boost effected a 29% increase in mean SBR in six serial dilutions of ICG. Intraoperative boost was performed in 11 patients including meningioma, glioblastoma multiforme, and metastases. Increase in tumor fluorescence was pronounced under direct tumor visualization. Across all patients, boost excitation resulted in 35% mean improvement from pre-boost SBR (p < 0.001). Conclusion: Neurosurgical microscopes remain the preferred method of visualizing tumor during intracranial surgery. However, current modalities for NIR signal detection are suboptimal. We demonstrate that augmentation of a fluorescence microscope module with a focused excitation source is a simple mechanism of improving NIR tumor visualization. Clinical trial registration: NCT03262636 [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Comparison of Near-Infrared Imaging Camera Systems for Intracranial Tumor Detection.
- Author
-
Cho, Steve S., Zeh, Ryan, Pierce, John T., Salinas, Ryan, Singhal, Sunil, and Lee, John Y. K.
- Subjects
- *
INTRACRANIAL tumors , *NEAR infrared spectroscopy , *AMINOLEVULINIC acid , *FLUOROPHORES , *INDOCYANINE green , *DIAGNOSIS , *PHOTOGRAPHIC equipment , *BRAIN tumors , *BREAST tumors , *COMPARATIVE studies , *DIAGNOSTIC imaging , *NONIONIZING radiation , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *EVALUATION research , *INDOLE compounds ,BRAIN tumor diagnosis - Abstract
Purpose: Distinguishing neoplasm from normal brain parenchyma intraoperatively is critical for the neurosurgeon. 5-Aminolevulinic acid (5-ALA) has been shown to improve gross total resection and progression-free survival but has limited availability in the USA. Near-infrared (NIR) fluorescence has advantages over visible light fluorescence with greater tissue penetration and reduced background fluorescence. In order to prepare for the increasing number of NIR fluorophores that may be used in molecular imaging trials, we chose to compare a state-of-the-art, neurosurgical microscope (System 1) to one of the commercially available NIR visualization platforms (System 2).Procedures: Serial dilutions of indocyanine green (ICG) were imaged with both systems in the same environment. Each system's sensitivity and dynamic range for NIR fluorescence were documented and analyzed. In addition, brain tumors from six patients were imaged with both systems and analyzed.Results: In vitro, System 2 demonstrated greater ICG sensitivity and detection range (System 1 1.5-251 μg/l versus System 2 0.99-503 μg/l). Similarly, in vivo, System 2 demonstrated signal-to-background ratio (SBR) of 2.6 ± 0.63 before dura opening, 5.0 ± 1.7 after dura opening, and 6.1 ± 1.9 after tumor exposure. In contrast, System 1 could not easily detect ICG fluorescence prior to dura opening with SBR of 1.2 ± 0.15. After the dura was reflected, SBR increased to 1.4 ± 0.19 and upon exposure of the tumor SBR increased to 1.8 ± 0.26.Conclusion: Dedicated NIR imaging platforms can outperform conventional microscopes in intraoperative NIR detection. Future microscopes with improved NIR detection capabilities could enhance the use of NIR fluorescence to detect neoplasm and improve patient outcome. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
26. The second window ICG technique demonstrates a broad plateau period for near infrared fluorescence tumor contrast in glioblastoma.
- Author
-
Zeh, Ryan, Sheikh, Saad, Xia, Leilei, Pierce, John, Newton, Andrew, Predina, Jarrod, Cho, Steve, Nasrallah, MacLean, Singhal, Sunil, Dorsey, Jay, and Lee, John Y. K.
- Subjects
- *
INDOCYANINE green , *ANGIOGRAPHY , *GLIOBLASTOMA multiforme , *NEAR infrared radiation , *OPERATIVE surgery , *FLUORESCENCE - Abstract
Introduction: Fluorescence-guided surgery has emerged as a powerful tool to detect, localize and resect tumors in the operative setting. Our laboratory has pioneered a novel way to administer an FDA-approved near-infrared (NIR) contrast agent to help surgeons with this task. This technique, coined Second Window ICG, exploits the natural permeability of tumor vasculature and its poor clearance to deliver high doses of indocyanine green (ICG) to tumors. This technique differs substantially from established ICG video angiography techniques that visualize ICG within minutes of injection. We hypothesized that Second Window ICG can provide NIR optical contrast with good signal characteristics in intracranial brain tumors over a longer period of time than previously appreciated with ICG video angiography alone. We tested this hypothesis in an intracranial mouse glioblastoma model, and corroborated this in a human clinical trial. Methods: Intracranial tumors were established in 20 mice using the U251-Luc-GFP cell line. Successful grafts were confirmed with bioluminescence. Intravenous tail vein injections of 5.0 mg/kg (high dose) or 2.5 mg/kg (low dose) ICG were performed. The Perkin Elmer IVIS Spectrum (closed field) was used to visualize NIR fluorescence signal at seven delayed time points following ICG injection. NIR signals were quantified using LivingImage software. Based on the success of our results, human subjects were recruited to a clinical trial and intravenously injected with high dose 5.0 mg/kg. Imaging was performed with the VisionSense Iridium (open field) during surgery one day after ICG injection. Results: In the murine model, the NIR signal-to-background ratio (SBR) in gliomas peaks at one hour after infusion, then plateaus and remains strong and stable for at least 48 hours. Higher dose 5.0 mg/kg improves NIR signal as compared to lower dose at 2.5 mg/kg (SBR = 3.5 vs. 2.8; P = 0.0624). Although early (≤ 6 hrs) visualization of the Second Window ICG accumulation in gliomas is stronger than late (≥24 hrs) visualization (SBR = 3.94 vs. 2.32; p<0.05) there appears to be a long plateau period of stable ICG NIR signal accumulation within tumors in the murine model. We call this long plateau period the “Second Window” of ICG. In glioblastoma patients, the delayed visualization of intratumoral NIR signal was strong (SBR 7.50 ± 0.74), without any significant difference within the 19 to 30 hour visualization window (R2 = 0.019). Conclusion: The Second Window ICG technique allows neurosurgeons to deliver NIR optical contrast agent to human glioblastoma patients, thus providing real-time tumor identification in the operating room. This nonspecific tumor accumulation of ICG within the tumor provides strong signal to background contrast, and is not significantly time dependent between 6 hours to 48 hours, providing a broad plateau for stable visualization. This finding suggests that optimal imaging of the “Second Window of ICG” may be within this plateau period, thus providing signal uniformity across subjects. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
27. Operative Strategies to Minimize Complications Following Resection of Pituitary Macroadenomas.
- Author
-
Thawani, Jayesh P., Ramayya, Ashwin G., Pisapia, Jared M., Abdullah, Kalil G., Lee, John Y-K., and Grady, M. Sean
- Subjects
- *
VASOPRESSIN , *KIDNEY diseases , *LOGISTIC regression analysis , *ENDOCRINE diseases , *LUMBAR curve - Abstract
Introduction We sought to identify factors associated with increased length of stay (LOS) and morbidity in patients undergoing resection of pituitary macroadenomas. Methods We reviewed records of 203 consecutive patients who underwent endoscopic endonasal resection of a pituitary macroadenoma (mean age = 55.7 [16-88]) years, volume = 11.3 (1.0-134.3) cm3. Complete resection was possible in 60/29.6% patients. Mean follow-up was 575 days. Multivariate logistic regression was performed using MATLAB. Results Mean LOS was 4.67 (1-66) days and was associated with CSF leak (p = 0.025), lumbar drain placement (p = 0.041; n = 8/3.9% intraoperative, n = 20/9.9% postoperative), and any infection (p = 0.066). Age, diabetes insipidus (n = 17/8.37%), and syndrome of inappropriate antidiuretic hormone secretion (n = 12/5.9%) were not associated with increased LOS (p > 0.2). Postoperative CSF leak in the hospital (n = 21/ 10.3%) was associated with intraoperative CSF leak (p = 0.002; n = 82/40.4%) and complete resection (p = 0.012). There was no significant association (p > 0.1) between postoperative CSF leak in the hospital following surgery and the use of a fat graft (n = 61/30.1%), nasoseptal flap (155/76.4%), or perioperative lumbar drain placement (n = 8/3.94%). Conclusion Complete resection is associated with increased risk of CSF leak and LOS. Operative strategies including placement of fat graft, nasoseptal flap, or intraoperative lumbar drain placement may have limited value in reducing the risk of postoperative CSF leak. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
28. Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla.
- Author
-
Verma, Gaurav, Mohan, Suyash, Nasrallah, MacLean P., Brem, Steven, Lee, John Y. K., Chawla, Sanjeev, Wang, Sumei, Nagarajan, Rajakumar, Thomas, M. Albert, and Poptani, Harish
- Subjects
- *
HYDROXY acids , *ISOCITRATE dehydrogenase , *GLIOMAS , *PHOSPHOCHOLINE , *BRAIN tumors , *IMMUNOSTAINING , *ASTROCYTOMAS , *SPECTRUM analysis - Abstract
Background: Mutations in the isocitrate dehydrogenase enzyme are present in a majority of lower-grade gliomas and secondary glioblastomas. This mis-sense mutation results in the neomorphic reduction of isocitrate dehydrogenase resulting in an accumulation of the "oncometabolite" 2-hydroxyglutarate (2HG). Detection of 2HG can thus serve as a surrogate biomarker for these mutations, with significant translational implications including improved prognostication. Two dimensional localized correlated spectroscopy (2D L-COSY) at 7T is a highly-sensitive non-invasive technique for assessing brain metabolism. This study aims to assess tumor metabolism using 2D L-COSY at 7T for the detection of 2HG in IDH-mutant gliomas. Methods: Nine treatment-naï ve patients with suspected intracranial neoplasms were scanned at 7T MRI/MRS scanner using the 2D L-COSY technique. 2D-spectral processing and analyses were performed using a MATLAB-based reconstruction algorithm. Cross and diagonal peak volumes were quantified in the 2D L-COSY spectra and normalized with respect to the creatine peak at 3.0 ppm and quantified data were compared with previously-published data from six normal subjects. Detection of 2HG was validated using findings from immunohistochemical (IHC) staining in patients who subsequently underwent surgical resection. Results: 2HG was detected in both of the IDH-mutated gliomas (grade III Anaplastic Astrocytoma and grade II Diffuse Astrocytoma) and was absent in IDH wild-type gliomas and in a patient with breast cancer metastases. 2D L-COSY was also able to resolve complex and overlapping resonances including phosphocholine (PC) from glycerophosphocholine (GPC), lactate (Lac) from lipids and glutamate (Glu) from glutamine (Gln). Conclusions: This study demonstrates the ability of 2D L-COSY to unambiguously detect 2HG in addition to other neuro metabolites. These findings may aid in establishing 2HG as a biomarker of malignant progression as well as for disease monitoring in IDH-mutated gliomas. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
29. Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases.
- Author
-
Chowdhury, Imran H., Ojerholm, Eric, McMillan, Matthew T., Miller, Denise, Kolker, James D., Kurtz, Goldie, Dorsey, Jay F., Nagda, Suneel N., Geiger, Geoffrey A., Brem, Steven, O’Rourke, Donald M., Zager, Eric L., Gangadhar, Tara, Schuchter, Lynn, Lee, John Y. K., and Alonso-Basanta, Michelle
- Abstract
Purpose: Stereotactic radiosurgery (SRS) alone is an increasingly common treatment strategy for brain metastases. However, existing prognostic tools for overall survival (OS) were developed using cohorts of patients treated predominantly with approaches other than SRS alone. Therefore, we devised novel risk scores for OS and distant brain failure (DF) for melanoma brain metastases (MBM) treated with SRS alone. Methods and materials: We retrospectively reviewed 86 patients treated with SRS alone for MBM from 2009-2014. OS and DF were estimated using the Kaplan-Meier method. Cox proportional hazards modeling identified clinical risk factors. Risk scores were created based on weighted regression coefficients. OS scores range from 0-10 (0 representing best OS), and DF risk scores range from 0-5 (0 representing lowest risk of DF). Predictive power was evaluated using c-index statistics. Bootstrapping with 200 resamples tested model stability. Results: The median OS was 8.1 months from SRS, and 54 (70.1 %) patients had DF at a median of 3.3 months. Risk scores for OS were predicated on performance status, extracranial disease (ED) status, number of lesions, and gender. Median OS for the low-risk group (0-3 points) was not reached. For the moderate-risk (4-6 points) and high-risk (6.5-10) groups, median OS was 7.6 months and 2.4 months, respectively (p < .0001). Scores for DF were predicated on performance status, ED status, and number of lesions. Median time to DF for the low-risk group (0 points) was not reached. For the moderate-risk (1-2 points) and high-risk (3-5 points) groups, time to DF was 4.8 and 2.0 months, respectively (p < .0001). The novel scores were more predictive (c-index = 0.72) than melanoma-specific graded prognostic assessment or RTOG recursive partitioning analysis tools (c-index = 0.66 and 0.57, respectively). Conclusions: We devised novel risk scores for MBM treated with SRS alone. These scores have implications for prognosis and treatment strategy selection (SRS versus whole-brain radiotherapy). [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
30. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
- Author
-
Brastianos, Priscilla K, Taylor-Weiner, Amaro, Manley, Peter E, Jones, Robert T, Dias-Santagata, Dora, Thorner, Aaron R, Lawrence, Michael S, Rodriguez, Fausto J, Bernardo, Lindsay A, Schubert, Laura, Sunkavalli, Ashwini, Shillingford, Nick, Calicchio, Monica L, Lidov, Hart G W, Taha, Hala, Martinez-Lage, Maria, Santi, Mariarita, Storm, Phillip B, Lee, John Y K, and Palmer, James N
- Subjects
- *
GENETIC mutation , *CRANIOLOGY , *CARCINOMA , *BRAIN tumor treatment , *NUCLEOTIDE sequence , *GENETIC code - Abstract
Craniopharyngiomas are epithelial tumors that typically arise in the suprasellar region of the brain. Patients experience substantial clinical sequelae from both extension of the tumors and therapeutic interventions that damage the optic chiasm, the pituitary stalk and the hypothalamic area. Using whole-exome sequencing, we identified mutations in CTNNB1 (β-catenin) in nearly all adamantinomatous craniopharyngiomas examined (11/12, 92%) and recurrent mutations in BRAF (resulting in p.Val600Glu) in all papillary craniopharyngiomas (3/3, 100%). Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors). The CTNNB1 and BRAF mutations were clonal in each tumor subtype, and we detected no other recurrent mutations or genomic aberrations in either subtype. Adamantinomatous and papillary craniopharyngiomas harbor mutations that are mutually exclusive and clonal. These findings have important implications for the diagnosis and treatment of these neoplasms. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
31. Postoperative radiation therapy for low-grade glioma.
- Author
-
Suneja, Gita, Alonso-Basanta, Michelle, Lustig, Robert, Lee, John Y. K., and Bekelman, Justin E.
- Subjects
- *
CANCER radiotherapy , *GLIOMA treatment , *ASTROCYTOMAS , *POSTOPERATIVE period , *REGRESSION analysis , *ADJUVANT treatment of cancer , *DATA analysis - Abstract
BACKGROUND: The role of postoperative radiotherapy (PORT) in the management of low-grade glioma remains controversial. An analysis using data from the European Organization for Research and Treatment of Cancer 22844/22845 studies concluded that several factors portend a poor prognosis: age ≥40 years, astrocytoma histology, tumor size ≥6 cm, tumor crossing midline, and preoperative neurologic deficits. PORT may benefit patients with high-risk features. The aim of this study was to assess temporal trends and determinants of the use of PORT. METHODS: By using data from the Surveillance, Epidemiology, and End Results program, the authors identified 1127 adult patients diagnosed with low-grade glioma (World Health Organization grade I and II) who underwent surgical resection between January 1, 1998 and December 31, 2006. The primary outcome was receipt of PORT. The authors performed multivariate logistic regression to examine the association between clinical, patient, and demographic characteristics and receipt of PORT. RESULTS: Receipt of PORT declined during the study period, from 64% of patients in 1998 to 36% of patients in 2006. On multivariate analysis, significant predictors of receipt of PORT were age ≥40 years, tumor crossing midline, and partial surgical resection. CONCLUSIONS: The use of PORT for patients with low-grade glioma has declined in the period from 1998 to 2006 for both low-risk and high-risk patients. Cancer 2012. © 2011 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
32. Robot-assisted anterior lumbar interbody fusion (ALIF) using retroperitoneal approach.
- Author
-
Kim, Minji J., Yoon Ha, Moon Sool Yang, Do Heum Yoon, Keung Nyun Kim, Hoon Kim, Joong Won Yang, Lee, John Y. K., Seong Yi, Woo Joo Jung, and Koon Ho Rha
- Subjects
- *
MEDICAL robotics , *SURGICAL robots , *LAPAROSCOPIC surgery , *LEARNING curve , *SPINAL surgery - Abstract
Over the past few years, robot-assisted surgery has become increasingly popular, affecting virtually all surgical fields. It has been proven to overcome pitfalls of laparoscopic procedures, such as high complication rates and steep learning curve. We have, therefore, performed experimental anterior lumbar interbody fusion (ALIF) using retroperitoneal approach in swine model to test the feasibility of robot-assisted surgery in spinal surgery. In this report, we describe the setup with the da Vinci® surgical system, operative method, result and discuss technical aspects and the future of robot-assisted ALIF. Experimental retroperitoneal dissection using robotic surgical system was successfully performed with great visual cue, minimal retraction and minimal bleeding. Although retroperitoneal approach for spinal fusion has never been attempted with robotic surgical system, we could demonstrate the possibility with swine model. Further studies and development of appropriate instruments will bring minimally invasive spine surgery to a new era. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
33. Intraoperative molecular imaging clinical trials: a review of 2020 conference proceedings.
- Author
-
Azari, Feredun, Kennedy, Gregory, Bernstein, Elizabeth, Hadjipanayis, Costas, Vahrmeijer, Alexander L., Smith, Barbara L., Rosenthal, Eben, Sumer, Baran, Tian, Jie, Henderson, Eric R., Lee, Amy, Nguyen, Quyen, Gibbs, Summer L., Pogue, Brian W., Orringer, Daniel A., Charalampaki, Patra, Martin, Linda W., Tanyi, Janos L., Kenneth Lee, Major, and Lee, John Y. K.
- Subjects
- *
CLINICAL trials , *SURGICAL margin , *OPERATIVE surgery , *ONCOLOGIC surgery , *SURGICAL robots , *DIAGNOSTIC imaging - Abstract
Significance: Surgery is often paramount in the management of many solid organ malignancies because optimal resection is a major factor in disease-specific survival. Cancer surgery has multiple challenges including localizing small lesions, ensuring negative surgical margins around a tumor, adequately staging patients by discriminating positive lymph nodes, and identifying potential synchronous cancers. Intraoperative molecular imaging (IMI) is an emerging potential tool proposed to address these issues. IMI is the process of injecting patients with fluorescent-targeted contrast agents that highlight cancer cells prior to surgery. Over the last 5 to 7 years, enormous progress has been achieved in tracer development, near-infrared camera approvals, and clinical trials. Therefore, a second biennial conference was organized at the University of Pennsylvania to gather surgical oncologists, scientists, and experts to discuss new investigative findings in the field. Our review summarizes the discussions from the conference and highlights findings in various clinical and scientific trials. Aim: Recent advances in IMI were presented, and the importance of each clinical trial for surgical oncology was critically assessed. A major focus was to elaborate on the clinical endpoints that were being utilized in IMI trials to advance the respective surgical subspecialties. Approach: Principal investigators presenting at the Perelman School of Medicine Abramson Cancer Center's second clinical trials update on IMI were selected to discuss their clinical trials and endpoints. Results: Multiple phase III, II, and I trials were discussed during the conference. Since the approval of 5-ALA for commercial use in neurosurgical malignancies, multiple tracers and devices have been developed to address common challenges faced by cancer surgeons across numerous specialties. Discussants also presented tracers that are being developed for delineation of normal anatomic structures that can serve as an adjunct during surgical procedures. Conclusions: IMI is increasingly being recognized as an improvement to standard oncologic surgical resections and will likely advance the art of cancer surgery in the coming years. The endpoints in each individual surgical subspecialty are varied depending on how IMI helps each specialty solve their clinical challenges. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. Glycerol rhizotomy via a retrosigmoid approach as an alternative treatment for trigeminal neuralgia.
- Author
-
Goodwin, C. Rory, Yang, Jesse X., Bettegowda, Chetan, Hwang, Brian, James, Carol, Biser, Ann, Raza, Shaan, Bender, Matthew, Carson, Benjamin, Lee, John Y. K., and Lim, Michael
- Subjects
- *
TRIGEMINAL neuralgia , *TRIGEMINAL nerve , *SURGICAL decompression , *GLYCERIN , *MAGNETIC resonance imaging , *SURGERY - Abstract
Objectives: Trigeminal neuralgia is a sensory nerve disorder characterized by lancinating pain and treated most commonly with carbamazepine, rhizotomy treatment, or open surgical management with microvascular decompression. We describe a novel technique to complement surgical treatment for trigeminal neuralgia via direct injection of the trigeminal nerve with glycerin in the cisternal portion of the nerve. Patients and methods: We performed a retrospective analysis of patients who received standard microvascular decompression and injection of glycerin to the inferior third of the cisternal portion of the nerve anterior to the root entry zone with lack of a compressive vessel on MRI as the primary indication. Fourteen patients were identified and demographic information, post-operative course and complications were recorded. Results: There were eleven females and three males with an average age at time of surgery of 54.8 years. 100% of patients reported that their trigeminal pain was significantly improved following surgical intervention. Four out of fourteen patients reported a 50-80% decrease from the pre-surgery baseline pain at one month and three month follow up. One patient developed a CSF leak, and no surgical site infections or motor deficits were observed. Conclusion: Intra-operative glycerin rhizotomy in conjunction with microvascular decompression can be used to safely treat patients suffering from trigeminal neuralgia. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
35. Reconstructive Challenges in the Extended Endoscopic Transclival Approach.
- Author
-
Kamat, Ameet R., Goldstein, Gregg, Palmer, James N., Lee, John Y. K., Newman, Jason G., and Adappa, Nithin D.
- Subjects
- *
ENDOSCOPIC surgery , *SKULL base , *TUMORS - Abstract
An abstract of a study which examined patients undergoing extended endoscopic approach (EEA) for skull base tumors is presented.
- Published
- 2013
- Full Text
- View/download PDF
36. Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases.
- Author
-
Chowdhury, Imran H, Ojerholm, Eric, McMillan, Matthew T, Miller, Denise, Kolker, James D, Kurtz, Goldie, Dorsey, Jay F, Nagda, Suneel N, Geiger, Geoffrey A, Brem, Steven, O'Rourke, Donald M, Zager, Eric L, Gangadhar, Tara, Schuchter, Lynn, Lee, John Y K, and Alonso-Basanta, Michelle
- Abstract
Purpose: Stereotactic radiosurgery (SRS) alone is an increasingly common treatment strategy for brain metastases. However, existing prognostic tools for overall survival (OS) were developed using cohorts of patients treated predominantly with approaches other than SRS alone. Therefore, we devised novel risk scores for OS and distant brain failure (DF) for melanoma brain metastases (MBM) treated with SRS alone.Methods and Materials: We retrospectively reviewed 86 patients treated with SRS alone for MBM from 2009-2014. OS and DF were estimated using the Kaplan-Meier method. Cox proportional hazards modeling identified clinical risk factors. Risk scores were created based on weighted regression coefficients. OS scores range from 0-10 (0 representing best OS), and DF risk scores range from 0-5 (0 representing lowest risk of DF). Predictive power was evaluated using c-index statistics. Bootstrapping with 200 resamples tested model stability.Results: The median OS was 8.1 months from SRS, and 54 (70.1 %) patients had DF at a median of 3.3 months. Risk scores for OS were predicated on performance status, extracranial disease (ED) status, number of lesions, and gender. Median OS for the low-risk group (0-3 points) was not reached. For the moderate-risk (4-6 points) and high-risk (6.5-10) groups, median OS was 7.6 months and 2.4 months, respectively (p < .0001). Scores for DF were predicated on performance status, ED status, and number of lesions. Median time to DF for the low-risk group (0 points) was not reached. For the moderate-risk (1-2 points) and high-risk (3-5 points) groups, time to DF was 4.8 and 2.0 months, respectively (p < .0001). The novel scores were more predictive (c-index = 0.72) than melanoma-specific graded prognostic assessment or RTOG recursive partitioning analysis tools (c-index = 0.66 and 0.57, respectively).Conclusions: We devised novel risk scores for MBM treated with SRS alone. These scores have implications for prognosis and treatment strategy selection (SRS versus whole-brain radiotherapy). [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
37. Robot-assisted anterior lumbar interbody fusion in a Swine model in vivo test of the da vinci surgical-assisted spinal surgery system.
- Author
-
Yang MS, Yoon do H, Kim KN, Kim H, Yang JW, Yi S, Lee JY, Jung WJ, Rha KH, Ha Y, Yang, Moon Sool, Yoon, Do Heum, Kim, Keung Nyun, Kim, Hoon, Yang, Joong Won, Yi, Seong, Lee, John Y K, Jung, Woo Ju, Rha, Koon Ho, and Ha, Yoon
- Abstract
Study Design: the use of the da Vinci Surgical System to perform an anterior lumbar interbody fusion in a swine model to identify the technical properties, processes, merits, demerits, and limitations of a video-assisted robotic surgical system.Objective: this study was designed to demonstrate the feasibility of using a robotic surgical system to perform spinal surgery.Summary Of Background Data: video-assisted laparoscopic anterior fusion was first reported in 1995 and afterward was spotlighted for several years. However, this technique has not become popular because of technical difficulties and complications associated with video-assisted procedures on the spine. As such, there is a demand for investigations to improve this technology. The da Vinci Surgical System provides 3-dimensional visualization as well as uniquely dexterous instruments that are remarkably similar to human hands. Video-assisted surgery with the da Vinci Surgical System robot has already provided great value to the fields of urology, cardiology, gynecology, and general surgery over the last decade. Preclinical studies for application of this system in spinal surgery have recently been conducted.Methods: a pig underwent anterior lumbar interbody fusion using da Vinci Surgical System assistance, with Tyche expandable cages used for preparation of endplates and cage placement. The setup time, operation time, amount of bleeding, and the number of complications associated with robotic manipulation were recorded. Before euthanasia, the animal underwent radiologic examination to confirm proper placement of cages.Results: the total duration of the procedure took 6 hours, with some complications related to frozen armsand robotic arm collision. Even so, there was neither any significant nerve or vessel injury nor peritoneal organ damage. Furthermore, radiologic assessment confirmed proper position of the cage in the center of the disc space.Conclusion: use of the da Vinci Surgical System to perform an anterior spinal procedure was shown to be safe and effective in a swine animal model. The utilization of this advanced technology shows promise to reduce the incidence of complications compared with other approaches. It requires further testing in animal models and cadavers, along with serial comparisons to current procedures. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.